| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maowen Ba, Min Kong, Lina Guan, Maoli Yi, Hongli Zhan. Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model. Oncotarget. vol 7. issue 37. 2018-01-29. PMID:27613848. |
fluctuations of dopamine levels and upregulations of nr2b tyrosine phosphorylation in the striatum have been connected with levodopa (l-dopa)-induced dyskinesia (lid) in parkinson's disease (pd). |
2018-01-29 |
2023-08-13 |
rat |
| Oscar Solís, Jose Ruben Garcia-Montes, Aldo González-Granillo, Ming Xu, Rosario Moratall. Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling. Cerebral cortex (New York, N.Y. : 1991). vol 27. issue 1. 2018-01-02. PMID:26483399. |
dopamine d3 receptor modulates l-dopa-induced dyskinesia by targeting d1 receptor-mediated striatal signaling. |
2018-01-02 |
2023-08-13 |
mouse |
| Eugenia V Gurevich, Raul R Gainetdinov, Vsevolod V Gurevic. G protein-coupled receptor kinases as regulators of dopamine receptor functions. Pharmacological research. vol 111. 2017-12-26. PMID:27178731. |
here we describe known effects of individual grks on dopamine receptors in cell culture and in the two in vivo models of dopamine-mediated signaling: behavioral response to psychostimulants and l-dopa- induced dyskinesia. |
2017-12-26 |
2023-08-13 |
Not clear |
| Elisabetta Tronci, Francesco Napolitano, Ana Muñoz, Camino Fidalgo, Francesca Rossi, Anders Björklund, Alessandro Usiello, Manolo Cart. BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats. Experimental neurology. vol 297. 2017-10-05. PMID:28757258. |
in addition to its role in neuronal survival, the brain neurotrophic factor (bdnf) has been shown to influence serotonin transmission and synaptic plasticity, events strongly implicated in the appearance of l-dopa-induced dyskinesia (lid), a motor complication occurring in parkinsonian patients after long-term treatment with the dopamine precursor. |
2017-10-05 |
2023-08-13 |
rat |
| Zhaofei Yang, Xuan Wang, Jian Yang, Min Sun, Yong Wang, Xiaomin Wan. Aberrant CpG Methylation Mediates Abnormal Transcription of MAO-A Induced by Acute and Chronic L-3,4-Dihydroxyphenylalanine Administration in SH-SY5Y Neuronal Cells. Neurotoxicity research. vol 31. issue 3. 2017-10-02. PMID:27981510. |
l-dopa-induced dyskinesia (lid) has consistently been related to l-dopa-derived excessive dopamine release, but the mechanisms have not been addressed very clear. |
2017-10-02 |
2023-08-13 |
Not clear |
| Jeffrey H Kordower, Angel Vinuela, Yaping Chu, Ole Isacson, D Eugene Redmon. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. The Journal of comparative neurology. vol 525. issue 3. 2017-09-13. PMID:27418401. |
parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. |
2017-09-13 |
2023-08-13 |
monkey |
| Jeffrey H Kordower, Angel Vinuela, Yaping Chu, Ole Isacson, D Eugene Redmon. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. The Journal of comparative neurology. vol 525. issue 3. 2017-09-13. PMID:27418401. |
clinical trials testing the hypothesis that fetal dopamine grafts would provide antiparkinsonian benefit in patients who had already developed side effects from their long-term use of l-dopa revealed, in some cases, the presence of dyskinesias even in the absence of l-dopa. |
2017-09-13 |
2023-08-13 |
monkey |
| Jeffrey H Kordower, Angel Vinuela, Yaping Chu, Ole Isacson, D Eugene Redmon. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. The Journal of comparative neurology. vol 525. issue 3. 2017-09-13. PMID:27418401. |
these studies support the development of future dopamine neuron cell transplantation therapy-based approaches, indicating that in relevant primate models with appropriate cell preparation methodology, with successful graft survival and putamenal dopamine innervation, there is no evidence of graft-induced dyskinesias. |
2017-09-13 |
2023-08-13 |
monkey |
| Philippe De Deurwaerdère, Giuseppe Di Giovanni, Mark J Milla. Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry. Progress in neurobiology. vol 151. 2017-07-11. PMID:27389773. |
accordingly, l-dopa, the metabolic precursor of dopamine (da), is well-established as a treatment for the motor deficits of parkinson's disease despite long-term complications such as dyskinesia and psychiatric side-effects. |
2017-07-11 |
2023-08-13 |
Not clear |
| Dhanya Vijayakumar, Joseph Jankovi. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. vol 76. issue 7. 2017-03-08. PMID:27091215. |
peak-dose dyskinesia is treated mainly by reducing individual doses of levodopa and adding amantadine and dopamine agonists, whereas off-period dystonia often responds to baclofen and botulinum toxin injections. |
2017-03-08 |
2023-08-13 |
Not clear |
| Nicolas Morin, Marc Morissette, Laurent Grégoire, Thérèse Di Paol. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias. Current neuropharmacology. vol 14. issue 5. 2017-01-17. PMID:26639458. |
mglu5, dopamine d2 and adenosine a2a receptors in l-dopa-induced dyskinesias. |
2017-01-17 |
2023-08-13 |
rat |
| Melissa M Conti, Adam A A Goldenberg, Alexandra Kuberka, Mohamed Mohamed, Satie Eissa, David Lindenbach, Christopher Bisho. Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats. Pharmacology, biochemistry, and behavior. vol 142. 2016-10-31. PMID:26791104. |
although dopamine replacement therapy with l-dopa in parkinson's disease initially reduces motor symptoms, its chronic use often leads to the development of abnormal involuntary movements known as l-dopa-induced dyskinesia. |
2016-10-31 |
2023-08-13 |
rat |
| Heinz Reichman. Modern treatment in Parkinson's disease, a personal approach. Journal of neural transmission (Vienna, Austria : 1996). vol 123. issue 1. 2016-10-11. PMID:26293352. |
the rationale behind this recommendation has its origins in the side effects associated with each of these drug classes: whilst levodopa leads to dyskinesia, which may not be relevant for patients with a limited life-expectancy, dopamine agonists have a much longer plasma half life which probably leads to more continuous dopamine receptor stimulation and thus decreases the occurrence and severity of dyskinesia. |
2016-10-11 |
2023-08-13 |
Not clear |
| Charlotte A Haaxma, Martin W I M Horstink, Jan C Zijlmans, Wim A J G Lemmens, Bastiaan R Bloem, George F Bor. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease. Journal of Parkinson's disease. vol 5. issue 4. 2016-09-29. PMID:26444087. |
risk of disabling response fluctuations and dyskinesias for dopamine agonists versus levodopa in parkinson's disease. |
2016-09-29 |
2023-08-13 |
Not clear |
| Charlotte A Haaxma, Martin W I M Horstink, Jan C Zijlmans, Wim A J G Lemmens, Bastiaan R Bloem, George F Bor. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease. Journal of Parkinson's disease. vol 5. issue 4. 2016-09-29. PMID:26444087. |
response fluctuations and dyskinesias develop during the use of both levodopa (ld) and dopamine agonists (da), but may not be equally disabling. |
2016-09-29 |
2023-08-13 |
Not clear |
| D Tomas, D Stanic, H K Chua, K White, W C Boon, M Horn. Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease. PloS one. vol 11. issue 4. 2016-08-26. PMID:27077649. |
restoration of the dopamine transporter through cell therapy improves dyskinesia in a rat model of parkinson's disease. |
2016-08-26 |
2023-08-13 |
human |
| D Tomas, D Stanic, H K Chua, K White, W C Boon, M Horn. Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease. PloS one. vol 11. issue 4. 2016-08-26. PMID:27077649. |
the dyskinesia of parkinson's disease is most likely due to excess levels of dopamine in the striatum. |
2016-08-26 |
2023-08-13 |
human |
| D Tomas, D Stanic, H K Chua, K White, W C Boon, M Horn. Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease. PloS one. vol 11. issue 4. 2016-08-26. PMID:27077649. |
in this study we have examined the proposition that reinstating dopamine transporter expression in the striatum would reduce dyskinesia. |
2016-08-26 |
2023-08-13 |
human |
| D Tomas, D Stanic, H K Chua, K White, W C Boon, M Horn. Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease. PloS one. vol 11. issue 4. 2016-08-26. PMID:27077649. |
there was a reduction in dyskinesia in rats that received grafts expressing the dopamine transporter. |
2016-08-26 |
2023-08-13 |
human |
| D Tomas, D Stanic, H K Chua, K White, W C Boon, M Horn. Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease. PloS one. vol 11. issue 4. 2016-08-26. PMID:27077649. |
strategies designed to increase dopamine transporter in the striatum may be useful in treating the dyskinesia associated with human parkinson's disease. |
2016-08-26 |
2023-08-13 |
human |